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synthetic, non-intoxicating 
8,9-dihydrocannabidiol for the 
mitigation of seizures
Mark Mascal1, Nema Hafezi1, Deping Wang1, Yuhan Hu2, Gessica Serra2, Mark L. Dallas2 & 
Jeremy P. E. Spencer2
There can be a fine line between therapeutic intervention and substance abuse, and this point is 
clearly exemplified in herbal cannabis and its products. Therapies involving cannabis have been the 
treatment of last resort for some cases of refractory epilepsy, and this has been among the strongest 
medical justifications for legalization of marijuana. In order to circumvent the narcotic effects of 
Δ9-tetrahydrocannabinol (THC), many studies have concentrated on its less intoxicating isomer 
cannabidiol (CBD). However, CBD, like all natural cannabinoids, is a controlled substance in most 
countries, and its conversion into THC can be easily performed using common chemicals. We describe 
here the anticonvulsant properties of 8,9-dihydrocannibidiol (H2CBD), a fully synthetic analogue 
of CBD that is prepared from inexpensive, non-cannabis derived precursors. H2CBD was found to 
have effectiveness comparable to CBD both for decreasing the number and reducing the severity of 
pentylenetetrazole-induced seizures in rats. Finally, H2CBD cannot be converted by any reasonable 
synthetic route into THC, and thus has the potential to act as a safe, noncontroversial drug for seizure 
mitigation.
There is currently a great deal of research activity around the potential for phytocannabinoids, i.e. compounds 
that occur naturally in the hemp plant (Cannabis sativa), to treat a wide range of medical conditions, including 
anxiety, glaucoma, epilepsy, spasticity, inflammation, neurodegenerative diseases, affective disorders, and even 
cancer1,2. Indeed, a Medline database search using the term “cannabis” returns >14,000 journal hits since the 
year 2000, including nearly 900 literature reviews with cannabis- or a cannabinoid-related term in the title. The 
opportunities around the therapeutic potential of cannabinoids are however weighed against a range of draw-
backs, including adverse health effects, potential for abuse, cognitive and motor impairment, psychiatric dis-
turbances, legal issues, and the environmental impacts of marijuana cultivation3–5. Beyond this, herbal cannabis 
has been shown to contain >500 chemical entities, including around 100 cannabinoids alongside a variety of 
other terpenes, phenolics, flavonoids, lipids, and steroids, the toxicity and mutagenic nature of which are largely 
unexplored6,7. Of the two major cannabinoids that occur in cannabis, i.e. ∆9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD) (Fig. 1), the deleterious effects (intoxication, ataxia, tachycardia, somnolence, dry mouth, 
and hyperphagia) are primarily attributed to the former, and for that reason CBD has often been singled out for 
pharmacological investigations8.
While the use of CBD appears to circumvent most of the drawbacks of using cannabis preparations, there 
remain significant issues associated with its use: (1) All marijuana extracts, including CBD, are controlled 
substances in most countries, although some have decriminalized the use of cannabis primarily for therapeu-
tic purposes. (2) CBD is derived by extraction from the cannabis plant. A wide range of impurities may be 
present, and there is a growing concern for contamination by pesticides9, particularly in the current, largely 
unregulated climate. (3) Even if pure CBD is marketed, the deliberate chemical conversion of CBD to THC 
is technically trivial10,11. Were CBD to become freely available, it could lead to a culture similar to that of the 
pseudoephedrine-to-methamphetamine “meth lab” phenomenon, except that conversion of CBD to THC would 
involve a logistically far simpler chemical transformation. Pure THC, containing no CBD to antagonize its psycho-
tropic effects12, is a potentially dangerous drug. (4) A collateral liability of the derivation of CBD from cannabis is the 
cultivation of hemp, with potential environmental impacts in terms of heavy water usage and pesticide/herbicide 
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effluent burden. Legalization of marijuana will inevitably also lead to private cultivation using methods not 
intended to manage potential environmental damage. (5) Finally, the impact of legalized cannabis on healthcare 
systems, which in the US has been recently highlighted in the areas of accidental injuries13, unintentional inges-
tion of cannabis edibles by children14, and reproductive health15,16, may be considerable.
Among the potential medical indications of cannabis, it can be argued that its highest profile use is as an antie-
pileptic. Epilepsy is the general term given to a spectrum of conditions characterized by recurrent, unpredictable 
seizures, the consequences of which often have a profound effect on quality of life. Historical and anecdotal evi-
dence, along with a number of case studies documenting the practically unique efficacy of cannabis to treat some 
refractory cases of epilepsy17,18, have led to strong advocacy in favor of the legalization of marijuana19. This has 
recently culminated in US Food and Drug Administration (FDA) approval of Epidiolex (purified herbal CBD) for 
the treatment of Lennox-Gastaut and Dravet syndromes. Preclinical evidence for anticonvulsant activity of CBD 
and THC in acute animal models of seizures is also strong20,21.
Here, we describe the antiepileptic potential of 8,9-dihydrocannabidiol (H2CBD), a synthetic cannabinoid 
that differs structurally from CBD only by the saturation of the exocyclic carbon-carbon double bond. An imme-
diate advantage of H2CBD is that, despite its similarity to CBD, it is not present in cannabis extracts and therefore 
not presently a controlled substance. Importantly, there is no reasonable synthetic route for the conversion of 
H2CBD to THC, in stark contrast to CBD itself. Although H2CBD has been prepared from natural CBD22, we 
opted to employ an efficient, fully synthetic approach in order to avoid the intermediacy of any scheduled sub-
stance and thereby also circumvent any necessity for the cultivation of hemp to supply H2CBD.
H2CBD has previously been the subject of a limited number of studies involving cannabinoid pharmacology. 
Consistent with CBD, H2CBD shows (1) an inhibitory effect on cytochrome P45023,24, which can be measured by 
CO complex formation during hepatic microsomal metabolism of H2CBD25,26, and (2) antioxidant activity quan-
tified by inhibition of the production of reactive oxygen intermediates, nitric oxide, and tumor necrosis factor 
in murine macrophages27. While there is evidence to show that the documented sedative effects of CBD28,29 may 
be due to in vivo conversion to THC in the acidic gastric environment30,31, H2CBD, which cannot undergo this 
reaction, shows little if any evidence of narcotic activity32.
Mechanistically, synaptic transmission can be regulated by activation of the cannabinoid receptor CB1, and 
endocannabinoids are known to play a protective role in central nervous system disorders, particularly those 
associated with neuronal hyperexcitability33. Herbal cannabinoids are CB1 agonists and have been shown to 
exhibit CB1 receptor-dependent anticonvulsant activity in models of epilepsy34, while conversely, the application 
of the CB1 receptor antagonists induces epileptiform activity in these models35. However, the precise role of CB1 
activation in seizure mitigation has yet to be fully elucidated, and the protein targets of CBD (and by analogy, 
H2CBD) have not all been identified, so we do not at this point propose a mechanistic interpretation of the action 
of H2CBD in this context.
Results and Discussion
A simple, one-step synthetic approach to H2CBD could be based on the work of Crombie and co-workers36. 
Optimization of this reaction led to the isolation of H2CBD in a 71% yield (Fig. 2). The route is economically 
practical at scale: α-Phellandrene 1 is an inexpensive natural fragrance chemical37, and olivetol 2 is also com-
mercially available but can be prepared in bulk using a two-step method starting from the flavor ingredient 
3-nonen-2-one38.
Figure 1. Structures of the natural cannabinoids and synthetic H2CBD.
Figure 2. Preparation of synthetic H2CBD. Reagents and conditions: a. p-toluenesulfonic acid monohydrate 
(0.3 eq), benzene, RT, 1 h.
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In the seizure mitigation study, a total of 60 male Wistar Han rats were randomly divided into 5 groups of 12 
animals each and received either vehicle (ethanol, Cremophor EL, 0.9% w/v saline; 2:1:17), vehicle plus a positive 
control (CBD; 200 mg kg−1), or vehicle plus H2CBD (50, 100, or 200 mg kg−1) via intraperitoneal injection one 
hour prior to administration of the convulsant agent pentylenetetrazole (PTZ; 85 mg kg−1 in 0.9% w/v saline). 
Seizure activity was monitored as described in the Methods Section.
An overall effect of treatment upon the percentage of animals that exhibited tonic-clonic seizures was 
found (χ2 (4) = 10.48; P = 0.033), where pairwise comparisons revealed that significantly fewer animals that 
received CBD (200 mg kg−1) or H2CBD (200 mg kg−1) exhibited tonic-clonic seizures than the vehicle treated 
group (P < 0.05 in both cases) (Fig. 3). Furthermore, maximum seizure severity was also affected by treatment 
(H = 18.96; P < 0.001), where pairwise comparisons revealed that animals that received CBD (200 mg kg−1) or 
H2CBD (200 mg kg−1) exhibited significantly less severe seizures as coded by the Racine scale than the vehicle 
treated group (vehicle median: 5 (4.25–5 IQR), H2CBD 200 mg kg−1: 2 (0.25–4.25 IQR), CBD 200 mg kg−1: 2 
(0.25–3.75 IQR), P < 0.001 in both cases).
Analysis of blood and brain tissue obtained from animals in each treatment group post-mortem revealed an 
overall effect of dosing upon blood (H = 17.00; P = 0.0019) and brain tissue (H = 15.76; P = 0.0034) arising from 
detection of significant concentrations of H2CBD (100 mg kg−1: P < 0.05 (blood); 200 mg kg−1: P < 0.01 (blood); 
P < 0.01 (brain)) and CBD (200 mg kg−1: P < 0.01 (brain)) when compared with the vehicle treated group (Fig. 3).
These results unequivocally demonstrate that H2CBD exhibits a dose-dependent anticonvulsant action in 
acute, PTZ-induced generalised seizures in rats, with a maximal protective effect comparable to a matching 
dose of the established anticonvulsant CBD39. While these preliminary data provide a clear indication for the 
use of H2CBD as an anticonvulsant agent, further work will establish the inherent pharmacokinetic profile of 
H2CBD which, for the purposes of this study, was assumed to be identical to CBD, although indications from the 
Figure 3. Effect of H2CBD upon acute, PTZ-induced primary generalised seizures in rat. Effects of vehicle, 
H2CBD (50, 100 200 mg kg−1), and CBD (200 mg kg−1) treatments upon (A) the proportion of animals 
exhibiting tonic-clonic seizures (gray shaded area) and (B) median (middle bars), interquartile range (upper 
and lower bars) and individual (•) maximum seizure severity, following PTZ administration. *P < 0.05; 
***P < 0.001. Error bars in (B) show SEM. n = 12 animals per group in each case. (C) Brain and (D) blood 
concentrations of H2CBD (50, 100 200 mg kg−1) and CBD (200 mg kg−1) assessed via post-mortem samples 
obtained 90 minutes after cannabinoid administration. n ≥ 5 animals per group. Plots show median (middle 
bars), interquartile range (upper and lower bars) and individual animal (•) results. *P < 0.05; **P < 0.01.
4Scientific RepoRts |          (2019) 9:7778  | https://doi.org/10.1038/s41598-019-44056-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
bioanalyte results suggest differences in plasma and brain concentration at matching doses (200 mg kg−1), despite 
a comparable anticonvulsant effect. This may suggest the magnitude of the anticonvulsant effect of H2CBD could 
be being attenuated by suboptimal dosing intervals, preventing the effect from being assessed at maximal drug 
concentration.
In conclusion, it has been demonstrated that prophylactic administration of H2CBD (200 mg kg−1) to rats 
significantly reduces incidence of tonic-clonic seizures as well as maximum seizure severity as compared to 
vehicle treatment, with a comparable anticonvulsant effect as seen in positive control CBD. We summarize the 
advantages of H2CBD over CBD as a potential antiepileptic drug as follows: (1) Being fully synthetic, H2CBD 
is not a controlled substance and thereby may circumvent legal issues surrounding cannabis-based therapies. 
(2) The preparative approach to H2CBD is efficient, inexpensive, and scalable. Unlike CBD, which has to be 
isolated from a mixture of hundreds of other extractives and may also be contaminated with pesticides, synthetic 
H2CBD is easy to obtain in pure form. (3) Preparation of H2CBD from readily available, non-cannabis based 
precursors eliminates the necessity to cultivate marijuana and its attendant social and environmental concerns. 
(4) The comparable antiepileptic activity between natural CBD and synthetic, racemic H2CBD suggest that both 
enantiomers of H2CBD have comparable potency, consistent with literature studies on unnatural (+)-CBD40. (5) 
In contrast to CBD, there is no pathway from H2CBD to THC, either in vivo or in the laboratory. Thus, assuming 
the principal medical justification for pursuing cannabis-based therapies is their extraordinary anticonvulsant 
activity, and that all other indications (anxiety, chronic pain, nausea, anorexia, etc) can be effectively managed 
with non-controversial drugs41, H2CBD may find application as a safer alternative in terms of its lack of abuse 
liability and absence of psychotropic effects.
Methods
H2CBD preparation. Chemicals were purchased from Sigma-Aldrich and used as received. Based on a pro-
cedure reported by Crombie and coworkers36, a solution of olivetol (1.72 g, 9.54 mmol) and food-grade α-phel-
landrene (1.41 g, 10.4 mmol, 1.09 eq) in benzene (5 mL) was treated with p-toluenesulfonic acid monohydrate 
(0.545 g, 2.87 mmol) and the mixture was allowed to stir at room temperature for 1 h. The solvent was removed in 
vacuo and the residue was purified by silica gel chromatography using a gradient elution (100% hexanes to 10% 
diethyl ether in hexanes) to give H2CBD (2.14 g, 71%) as a dark yellow oil. Spectroscopic data (1H-NMR, 13C-
NMR) were in full agreement with the literature.
Antiseizure study. Animals. Male, Wistar Han rats (70–110 g; Harlan, Bicester, UK) were housed on a 12 h 
light–dark cycle, with food and water available ad libitum. All experiments were conducted in accordance with 
the UK Animals Scientific Procedures Act 1986 under a UK Home Office license and ARRIVE guidelines for 
reporting experiments involving animals42,43. A total of 60 rats were used.
Drug administration. Animals were randomly divided into 5 groups of 12 animals per group and received 
either vehicle (ethanol, Cremophor EL and saline (0.9%w/v NaCl), 2:1:17), a positive control (CBD; 200 mg kg−1; 
Sigma-Aldrich UK) or 8,9-dihydrocannabidiol (H2CBD; 50, 100 or 200 mg kg−1) via intraperitoneal injection 
1 h prior to administration of the convulsant agent pentylenetetrazole (PTZ) to achieve brain cannabinoid Tmax. 
PTZ (85 mg kg−1 in 0.9%w/v NaCl) was administered intraperitoneally 1 h after drug or vehicle treatment. Seizure 
activity was video recorded for 30 min and video records blinded before offline review and coding using a mod-
ified Racine scale (0, normal behaviour; 0.5, abnormal behaviour; 1, isolated myoclonic jerk; 2, atypical clonic 
seizure; 3, bilateral forelimb clonus; 3.5, bilateral forelimb clonus with body twist; 4, tonic–clonic seizure with 
suppressed tonic phase; 5, fully developed tonic–clonic seizure).
Analysis of plasma and brain samples. 4,4-Dichlorodiphenyltrichloroethane (DDT, CAS: 50-29-3) was 
used as the internal analytical standard (IS). HPLC grade n-hexane, acetonitrile, water and ascorbic acid were 
purchased from Sigma Aldrich UK and Fisher Scientific. Stock standard solutions of CBD, H2CBD and DDT 
were prepared in acetonitrile (5 mg ml−1 and 1 mg mL−1) and stored at −20 °C until use. These were further 
diluted in acetonitrile:water (62:38), to achieve calibration concentrations of 0.1, 0.2, 0.5, 1, 5, 10 μg mL−1. Plasma 
samples were prepared for HPLC using a previously validated method44. Briefly, DDT (50 μg mL−1) was added 
to 150 μL of rat plasma sample as internal standard and plasma proteins were precipitated by the addition of ice 
cold acetonitrile (600 μL) followed by water (600 μL), with 1 min vortexing between additions. n-Hexane (3 mL) 
was added to each tube and following a 5 min vortex, tubes were centrifuged at 1160 × g for 15 min at 10 °C and 
the upper organic layer was carefully decanted by glass pipette and retained. The organic layer was evaporated to 
dryness under a stream of nitrogen at room temperature and reconstituted in 150 μL of the mixture of acetonitrile 
and water (62:38) prior to HPLC analysis.
For post-mortem brain analysis, brains were weighed and 1.5 x ice-cold solvent (90% acetonitrile; 10% water; 
0.1% ascorbic acid) (w/v) was added followed by homogenization for 1 min. DDT (50 μg mL−1) was added to 
each homogenized brain tissue as internal standard, samples were mixed and allowed to equilibrate overnight at 
−20 °C. Samples were then centrifuged at 3500 rpm for 15 min and the top layer retained. Samples were dried by 
SpeedVac concentrator at room temperature (Savant SPD131DDA, ThermoFisher Scientific, UK) and reconsti-
tuted in 150 μL of the mixture of acetonitrile and water (62:38) for HPLC analysis.
An Agilent 1200 series HPLC (Hewlett–Packard, Palo Alto, CA, USA) equipped with a photodiode array 
detector was used for analysis. 30 μl of all samples were injected and separation was achieved using an ACE 
C18-PFP 150 mm 4.6 mm, 3 μm particle size column (Hichrom Ltd., Reading, UK), protected by an ACE 
C18-PFP 3 μm guard cartridge. The mobile phase was a mixture of acetonitrile and water in a ratio of 62:38 (v/v). 
The flow rate was set at 1 mL min−1 and the column temperature was maintained at 55 °C. The absorbance of the 
compounds of interest (CBD and H2CBD) was monitored at 220 nm.
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Statistical procedures were performed using GraphPad Prism 7 (GraphPad Software, Inc., San Diego, CA, 
USA). A D’Agostino and Pearson normality test revealed that data describing maximum seizure severity and bio-
analyte concentrations were not normally distributed. Therefore, assessment of differences within groups of these 
data types were assessed by a Kruskal–Wallis test with post-hoc Dunn’s tests. Drug effects upon the percentage 
of animals exhibiting tonic-clonic seizures were assessed by a chi-squared test with post-hoc Fisher exact tests.
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